13D Filings
Day One Biopharmaceuticals, Inc.
DAWN
Amendment
Ownership

0.00%

Total Shares

0

Issuer CIK

1845337

Event Date

Apr 22, 2026

Accepted

Apr 27, 2026, 05:55 PM

Reporting Persons (4)
Joint Filing

This is a joint filing. The reported shares may overlap between reporting persons and should not be summed.

NameType% of ClassAggregateSole VotingShared Voting
AI Day1 LLC
Other
0.00%000
Access Industries Holdings LLC
Other
0.00%000
Access Industries Management, LLC
Other
0.00%000
Len Blavatnik
Individual
0.00%000
Disclosure Items (3)

Security Title

Common Stock, par value $0.0001 per share

Issuer Name

Day One Biopharmaceuticals, Inc.

Issuer Address

1800 Sierra Point Parkway, Brisbane, CA, 94005

The disclosure in Item 4 is hereby amended and supplemented by adding the following at the end thereof: On April 9, 2026, AI Day1 tendered all of its shares of Common Stock pursuant to the tender offer by Servier Detroit Inc. ("Purchaser") to purchase all of the issued and outstanding shares of Common Stock for $21.50 per share in cash, upon the terms and subject to the conditions described in the Offer to Purchase and related Letter of Transmittal filed with the SEC on Schedule TO on March 26, 2026 (the "Tender Offer"). Such shares were accepted by the Purchaser on April 23, 2026. On April 23, 2026, in connection with the consummation of the merger, each pre-funded warrant held by AI Day1 to purchase Common Stock was converted into the right to receive $21.4999 per warrant in cash.

Percentage of Class

Item 5 of the Schedule 13D is hereby amended and restated as follows: As a result of the Tender Offer, the Reporting Persons no longer have any beneficial ownership in the Common Stock.

Transactions

The information set forth in Item 4 of this Schedule 13D is incorporated by reference herein.

Shareholders

Not applicable.

Date of 5% Ownership

The Reporting Persons ceased to be beneficial owners of more than five percent of the Issuer's Common Stock on April 23, 2026.